Chris Picardo

Chris Picardo

Partner at Madrona
Seattle, Washington, United States

Chris Picardo is Partner at Madrona. Chris was Director of Finance and Business Intelligence at Rockets of Awesome and Private Equity Associate at The Invus Group, LLC. Chris is a Board Member at Aizen Therapeutics, Archon Biosciences and Terray Therapeutics, and a Board Observer at Vilya, Ovation, Knock and Unearth Technologies.

Madrona Leads Faye’s Series C; Chris (Madrona) Joins Board as Faye Reimagines Travel Insurance

Madrona is leading Faye’s Series C investment because Faye has built a better, autonomous traveler care platform and improved whole-trip travel insurance that addresses slow, confusing incumbent products. The firm highlights travel’s growing disruptions and says Faye’s product delivers faster, more usable protection and better claims experiences for modern travelers.

Palantir Alum Explains How AI is Used and Bought by the Federal Government

Nick LaRovere spent years at Palantir before co-founding Pryzm with friends, including a Lockheed Martin alum. And in this episode of Founded & Funded, Nick shares his inside account of how AI is actually being adopted inside the federal government, and what it takes to sell technology into that market. Pryzm is an AI-powered intelligence engine for government business development: it aggregates data across CRMs, email, Slack, and public procurement sources to help companies win contracts. Nick's argument is that by the time an opportunity appears on SAM.gov, the deal is already decided. In this episode, Madrona Partner Chris Picardo…

Building AI That Sells: Scaling Smarter with Luminance CEO Eleanor Lightbody

Entrepreneurs often ask: When do I know it's time to scale? Or, how do I lead when I wasn't the original founder? In this week's Founded & Funded, Madrona Partner Chris Picardo sits down with Eleanor Lightbody, CEO of Luminance, who shares how she took a promising AI product and built a company culture, go-to-market motion, and product strategy that's scaled 6x in just two years. Eleanor's candor and tactical insights on hiring, selling, and navigating founder dynamics make this a must-listen. Transcript: https://www.madrona.com/building-ai-that-sells-scaling-smarter-with-luminance-ceo-eleanor-lightbody/ Chapters: (00:00) Introduction (01:29) Eleanor's Career Journey (03:22) Joining Luminance and Initial Challenges (05:46) Navigating CEO…

Terray's Jacob Berlin on The AI-Powered Future of Medicine

Terray Therapeutics CEO Jacob Berlin returns to Founded & Funded after three years to share how the company has scaled from an ambitious startup to an industry leader in AI-driven biotech. Learn how Terray's proprietary hardware combined with the world's largest chemistry data set is powering new discoveries in small molecule drug development. Jacob also discusses how the company's $120M Series B fundraise will prepare their internal programs for clinical trials and further enhance their AI platform. He shares insights on where he sees the future of AI and drug design and dives into how founders can balance internal innovation…

Curt Medeiros on Revolutionizing Precision Medicine and Scaling Ovation

Imagine a future where healthcare isn't just reactive but deeply personalized — where every patient gets the right treatment at the right time based on a precise understanding of their biology. This is the future Ovation is building, and on this week's Founded & Funded, Madrona Partner Chris Picardo dives into it all with Ovation CEO Curt Medeiros. From transforming underutilized clinical data into rich multiomics datasets to forging industry-leading partnerships with companies like Illumina, Curt shares how Ovation is shaping the future of precision medicine. He also opens up about the challenges of building a scalable, privacy-first platform, the…

Archon's Jamie Lazarovits on Unlocking the Full Power of Antibodies With AI

What does it take to move from cutting-edge academic research to launching a biotech company that could transform medicine? In this week's episode of Founded & Funded, Madrona Partner Chris Picardo sat down with Jamie Lazarovitz, CEO and co-founder of Archon Biosciences, to uncover the story behind their groundbreaking protein-based biologics and their unique Antibody Cages (AbCs). From bootstrapping deep tech investments as a student to navigating the challenges of commercializing revolutionary science, Jamie shares the pivotal moments, tough decisions, and key lessons that led to Archon's creation. This isn't just a story for biotech enthusiasts — every founder can…

IA40 Spotlight: A-Alpha Bio's David Younger on machine learning in biotech, building cross-functional teams

This week on Founded & Funded, Partner Chris Picardo is talking with A-Alpha Bio Co-founder and CEO David Younger for our first Intelligent Application 40 Spotlight episode of 2023. We announced the 2022 IA40 winners in October, and A-Alpha was the first biotech company to make the list, which was no surprise to us. As one of our portfolio companies, we know the work David and his team are doing at the intersections of biological and data/computer sciences will change the world — but having a group of judges agree with us makes us all the more certain. Protein interactions…

Sila Co-founder and CEO Shamir Karkal on Crypto and Web3

In this episode of Founded and Funded, Madrona Partner Chris Picardo dives into the world of crypto and Web3 with Sila Co-Founder and CEO Shamir Karkal. Sila is a FinTech platform that provides payment infrastructure as a service and sits at the intersection of crypto rails and traditional financial services infrastructure — because as much as some people want to get away from the traditional financial system, crypto still needs to be able to plug into it. Shamir and Chris dive into the importance of this infrastructure, the ups and downs of the crypto market, the trends driving FinTech and…

Madrona investors say ETHDenver shows surging Web3 momentum, talent exodus from Web2, and new startup opportunities

Madrona Venture Group investors Maria Gilfoyle and Chris Picardo report strong momentum for Web3 after attending ETHDenver, noting growing consumer behavior shifts, new app categories, and a large talent migration from Web2 to Web3. They highlight the Pacific Northwest's relevance to Web3 and identify talent movement, future Ethereum work, and startup opportunities as key takeaways.

Investor Announces Investment in Trade Coffee, Marketplace Connecting 400+ Independent Roasters to National Subscribers

The author explains why their firm invested in Trade Coffee, a marketplace that helps independent roasters reach national customers and matches drinkers to 400+ blends through personalized subscriptions; Trade has shipped over one million bags and supported roasters during the pandemic. The post emphasizes growth in craft coffee and the rising importance of at-home coffee as remote work increases.

Organizations

See all 15
  • Madrona logo
    Madrona Partner, Investor 2017–2021 · current
  • Stealth Biotech Board Member 2024–present · current
  • Aizen Therapeutics Board Member 2024–present · current

Education

  • Williams College Bachelor of Arts (B.A.), Mathematics and English · 2009–2013

Online